ArticleJournal of ovarian research2026
Yangjingzhongyu Decoction regulates primordial follicle initiation via LncRNA-Smad1/AMPK dual pathways in diminished ovarian reserve.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTargeting the dysregulated initiation of primordial follicles represents a potential therapeutic breakthrough in managing pathological diminished ovarian reserve (DOR). Previous research has demonstrated that Yangjingzhongyu Decoction (YJZYD) promotes the transition from primordial to primary follicles by post-transcriptionally regulating Smad1 protein via the ovary-specific long non-coding RNA (LncRNA) LTCONS-00011173. This effect may be further supported by YJZYD’s ability to ameliorate oxidative stress in the follicular developmental microenvironment through modulation of the AMPK pathway. This study aims to integrate these two mechanistic axes to elucidate the holistic mechanism through which YJZYD modulates the primordial follicle microenvironment.
objectiveTo investigate YJZYD’s regulatory mechanism on the primordial follicle initiating microenvironment in DOR rats.
resultsIn DOR model rats, primordial and growing follicles significantly decreased (p < 0.05), accompanied by reduced E2 and AMH levels (p < 0.05) and elevated FSH (p < 0.05). Treatment with YJZYD-medicated serum increased counts of primordial/growing follicle counts (p < 0.05), with no significant difference between the high-dose group and the control group (p > 0.05). Additionally, YJZYD reduced FSH, increased E2 and AMH (p < 0.05). It also downregulated LTCONS-00011173 and upregulated Smad1 (p < 0.05). Furthermore, YJZYD elevated SOD activity and ATP content (p < 0.05) and reduced MDA levels (p < 0.05). Moreover, it suppressed PTEN expression, dose-dependently regulated MST and AMH (p < 0.05), and enhanced GDF9 expression at low dose (p < 0.05). Molecular docking identified Apigenin and Curcumin as key monomers targeting AMPK/SIRT1/MAPK pathway. Experimental validation of Apigenin replicated YJZYD’s effects on follicle numbers and hormone levels (p < 0.01).
conclusionYJZYD alleviates primordial follicle initiation inhibition by targeting the LTCONS-00011173/Smad1 axis, while concurrently improving the follicular microenvironment through AMPK/SIRT1/PGC-1α mediated oxidative stress repair and energy metabolism enhancement. This dual-pathway mechanism restores follicular factor balance and ovarian reserve function in DOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.